￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
The new generation ALK/ROS1 inhibitor Lorlatinib was granted breakthrough drug designation by the FDA

2025-10-19 11:44:20

Check Details
How effective is lorlatinib in the first-line treatment of metastatic non-small cell lung cancer?

2025-10-19 11:44:20

Check Details
Dosage and treatment regimen of Dacomitinib/Dozerun in the treatment of advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
New lung cancer drug dacomitinib has significant effect in treating Chinese patients

2025-10-19 11:44:20

Check Details
Efficacy and safety of dacomitinib in first-line treatment of metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
The efficacy of dacomitinib in the first-line treatment of advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Dacomitinib, a new targeted drug for lung cancer, can significantly extend the survival time of advanced lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
The advent of dacomitinib has changed the treatment landscape of EGFR-positive lung cancer!

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking dacomitinib

2025-10-19 11:44:20

Check Details
None

2025-10-19 11:44:20

Check Details
Phase III clinical trial of dacomitinib in the treatment of locally advanced or metastatic non-small cell lung cancer carrying EGFR_ Kanghule

2025-10-19 11:44:20

Check Details
What are the differences between the second-generation targeted drug for lung cancer, dacomitinib, and the first-generation drug?

2025-10-19 11:44:20

Check Details
Category
相关知识